
Biased stochastic motor dynamics drive bidirectional, processive translocation by the AAA+ disaggregase Hsp104: biorxiv.org/content/10.64898…

Countering deleterious phase transitions in ALS/FTD, PD, AD, and related disorders @Penn @PennMedicine @bb_upenn @BMBGGUPENN @PGGUPenn @PennNGG @CAMBUpenn

Biased stochastic motor dynamics drive bidirectional, processive translocation by the AAA+ disaggregase Hsp104: biorxiv.org/content/10.64898…

Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease: investors.biogen.com/news-re…

Reversing lysosomal dysfunction restores youthful state in aged hematopoietic stem cells: Cell Stem Cell cell.com/cell-stem-cell/full…

Phosphorylation Alters Long-Range Intramolecular Interactions in Tau: pubs.acs.org/jpcbfk/article/…

‘Light and sound’ therapy for Alzheimer’s flops in long-anticipated trial nature.com/articles/d41586-0…

Intrinsically disordered ligands for the control of receptor uptake by endocytosis: pnas.org/doi/10.1073/pnas.26…

Molecular interactions underlying selective partitioning of clients into MED1 and FUS condensates: pnas.org/doi/10.1073/pnas.26…

SCN1B intron 3 retention results in a nonsense-mediated decay–sensitive mRNA linked to developmental and epileptic encephalopathy: pnas.org/doi/10.1073/pnas.25…

Msp1, Cdc48, and Hsp104 coordinate quality control of import-impaired mitochondrial β-barrel proteins: cell.com/cell-reports/fullte…




Breaking news: Mild Alzheimer’s patients benefit from 40Hz sensory stimulation in national clinical trial. picower.mit.edu/news/mild-al…. #neuroscience #alzheimers #neurology @mitbrainandcog @sciencemit Video: Li-Huei Tsai recounts the discovery.

Single-cell transfer RNA sequencing reveals principles of translational regulation: biorxiv.org/content/10.64898…

QurAlis is excited to announce that the FDA has cleared the IND for QRL-201, our lead program for the treatment of ALS. This significant regulatory milestone clears the path for the initiation of our pivotal clinical trial for QRL-201 in the U.S. (CONQUR). We also announced final data from the dose-range finding phase from the ANQUR Phase 1/2 clinical trial of QRL-201 in ALS. Results demonstrated QRL-201 slowed disease progression as measured by ALSFRS-R by 50 percent (p<0.05), and showed statistically significant reductions in NfL and pNfH, biomarkers of axonal damage in ALS. QurAlis plans to initiate the CONQUR pivotal study in the first half of 2027; the ANQUR open-label extended dosing is ongoing in Canada, the UK, and the EU. QRL-201 is a first-in-class, potent antisense oligonucleotide precision therapeutic in development to restore STATHMIN-2 (STMN2) expression in ALS patients with the aim to modify disease progression and improve outcomes. STMN2 is a protein important for muscle innervation that is regulated by TDP-43 and downregulated in the majority of ALS patients. ANQUR is the first human trial exploring the hypothesis that restoration of STMN2 may be a suitable disease-modifying approach in ALS. Read more in our press release bit.ly/4Cafd88 #precisionmedicine #neurodegnerativediseases #neurologicaldiseases #ALS

Processing bodies promote lysosomal quality and cell survival during recovery from lysosomal damage: rupress.org/jcb/article/225/…